ScribnerB.H.Discussion.Trans Am Soc Art if Intem Organs1965; 11: 29.
2.
JebsenR.H., TenckhoffH., HoultJ.C.Natural history of uremic polyneuropathy and the effects of dialysis.New Engl J Med1967; 277: 327.
3.
BabbA.L., PopovichR.P., ChristopherT.G., ScribnerB.H.The genesis of the square meter-hour hypothesis.Trans Am Soc Artif Intern Organs1971; 17: 81.
4.
BabbA.L., FarrellP.C., UvelliD.A., ScribnerB.H.Hemodialyzer evaluation by examination of solute molecular spectra.Trans Am Soc Artif Intern Organs1972; 19: 98.
5.
BergstromJ., FurstP., ZimmennanL.Uremic middle mole cules exist and are biologically active.Clin Nephrol1979; 11: 229.
6.
ZimmennanL., BaldestenA., BergstromJ., FurstP.Isotacho phoretic separation of middle molecule peptides in uremic body fluids.Clin N∼phrol1980; 14: 183.
7.
SaitoA., KanazawaI., ChungT.G., MaedaK.Analytical study for separation of middle molecules.Artif Organs1980; 4(Suppl): 13.
8.
AsabaH., AlvestrandA., BergstromJ., FurstP., YahielV.Uremic middle molecules in non-dialyzed azotemic patients: Relation to symptoms and clinical biochemistries.Clin Nephrol1982; 17: 90.
9.
AsabaH., BergstromJ., FurstP., JohnsonC., YahielV.Plasma middle molecules in asymptomatic and ‘sick.’ uremic patients.Artif Organs1980; 4(Suppl): 137.
10.
ManN.K., CueilleG., ZingraffJ., BoudetJUremic neurotoxin in the middle molecular weight range.Artif Organs1980; 4: 116.
11.
ZimmennanL., JornvallH., BergstromJ., FurstP., SjovallJ.Characterization of a double conjugate in uremic body fluids. Glucuronidated o-hydroxyben-zoylglycine.Febs Letters1981; 129: 237.
SpustovaV., BergstromJ., GregorovaB., ZimmennanL., DzurikR.International Congress Series, Elsevier Publisher.1982 (in press).
15.
PopovichR.P., MoncriefJ.W.Kinetic modeling of peritoneal transport.Contr Nephrol1979; 17: 59.
16.
BergstromJ., AsabaH., FurstP., LindholmB.Middle molecules in chronic uremic patients treated with peritoneal dialysis. In: GahlG.M., KesselM., NolphK.D. eds. Advances in peritoneal dialysis.Amsterdam: Excerpta Medica, 1982: 47–53.
17.
FarrellP.C., RandersonD.H.Mass transfer kinetics in continuous ambulatory peritoneal dialysis. In: LegrainM.. ed. Continuous ambulatory peritoneal dialysis.Amsterdam: Excerpta Medica, 1980: 34–41.
18.
GutmanR.A., HuangA.T., BouknightN.S.Inhibitor of marrow thymidine incorporation from sera of patients with uremia.Kidney Int1980; 18: 715.
19.
ScigallaP., GudimV.I., IvanovaV.S., MoskalevaGPDie mittelmolekule als erythropoesehemnfaktoren im blut tenninal niereninsuffizienter kinder; Wirkung der mittelmolekule aus uramischem serum auf die pluripotenten knochenmarkstammzellen in -vivo.Dt Gesundh-Westen1980; 35: 1422.
20.
LindholmB., TegnerR., Tranaeus, BergstromJ.Progress of peripheral neuropathy (PN) during continuous ambulatory peritoneal dialysis (CAPD). ASAIO 28th Annual Meeting Proceedings 1982 (in press).
FarrellP.C., RandersonD.H.Comparison of CAPD with HD and IPD. In: GahlG.M., KesselM., NolphK.D. eds. Advances in peritoneal dialysis.Amsterdam: Excerpta Medica1981; 131–137.
23.
AsabaH., AlvestrandA., FurstP., BergstromJ.Clinical implications of uremic molecules in regular hemodialysis patients. Submitted for publication in Clin Nephrol 1982.
24.
BergstromJ., LindblomU., NoreeL-OPreservation of peripheral nerve function in severe uremia during treatment with low protein high calorie diet and surplus of essential amino acids.Acta Neurol Scand1975; 51: 99.